Renin-Angiotensin System Proteases and the Cardiometabolic Syndrome: Pathophysiological, Clinical and Therapeutic Implications

  • Guido Lastra
  • Camila Manrique
  • James R. Sowers
Part of the Proteases in Biology and Disease book series (PBAD, volume 7)


NADPH Oxidase Focal Adhesion Kinase International Diabetes Federation Arterioscler Thromb Vasc Biol CARDIOMETABOLIC Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abuissa H, Jones PG, Marso SP, O’Keefe JH Jr, 2005, Angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 46: 821–826PubMedCrossRefGoogle Scholar
  2. Aguilera G, Kapur S, Feuillan P, Sunar-Akbasak B, Bathia AJ, 1994, Developmental changes in angiotensin II receptor subtypes and AT1 receptor mRNA in rat kidney. Kidney Intl. 46: 973–979CrossRefGoogle Scholar
  3. Albu JB, Kovera AJ, Johnson JA, 2000. Fat distribution in health and obesity. Ann N.Y. Acad Sci. 904: 491–501PubMedCrossRefGoogle Scholar
  4. Alexander CM, Landsman PB, Teutsch SM, Haffner SM, 2003, NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of coronary artery disease among NHANES III participants age 50 years and older. Diabetes. 52: 1210–1214PubMedCrossRefGoogle Scholar
  5. Allen AM, Zhuo JL, 1999, Mendelsohn FAO. Localization of angiotensin II AT1 and AT2 receptors. J Am Soc Nephrol. 10: S23–S29PubMedGoogle Scholar
  6. Aneja A, El-Atat F, McFarlane SI, Sowers JR, 2004, Hypertension and obesity. Recent Prog Horm Res. 59: 169–205PubMedCrossRefGoogle Scholar
  7. Avogaro P, Crepaldi G, Enzi G, Tiengo A, 1967, Associazione di hiperlipidemia diabete mellito e obesita di medio grado. Acta Diabetol Lat. 4: 36–41CrossRefGoogle Scholar
  8. Bays H, Mandarino L, De Fronzo R, 2004, Role of the adipocyte, free fatty acids and ectopic fat in the pathogenesis of type 2 diabetes mellitus: Peroxisomal proliferators-activated receptor agonists provide a rationale therapeutic approach. J Clin Endocrinol Metab. 89: 463–478PubMedCrossRefGoogle Scholar
  9. Bergman RN, Van Citters GW, Mittelman SD, et al 2001, Central role of the adipocyte in the Metabolic Syndrome. J Investig Med. 49: 119–126PubMedCrossRefGoogle Scholar
  10. Berk BC, Corson MA, 1999, Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ Res. 80: 607–616Google Scholar
  11. Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG, 2001, Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. Am J Physiol Heart Circ Physiol. 281: H2337–H2365PubMedGoogle Scholar
  12. Blundell T, Sibanda BLK, Pearl L, 1983, Three dimensional structure, specificity and catalytic mechanism of renin. Nature. 304: 273–275PubMedCrossRefGoogle Scholar
  13. Booz GW, Baker KM, 1996, Role of type 1 and type 2 angiotensin receptors in angiotensin II – induced cardiomyocyte hypertrophy. Hypertension. 28: 635–640PubMedGoogle Scholar
  14. Brink M, Welen J, Delafontaine P, 1996, Angiotensin II causes weight loss and decreases Insulin-Like Growth Factor in rats through a pressor-independent mechanism. J Clin Invest. 97: 2509–2516PubMedGoogle Scholar
  15. Bunning P, Holmquist B, Riordan JF, 1983, Substrate, specificity and kinetic characteristics of angiotensin converting enzyme. Biochemistry. 22: 103–110PubMedCrossRefGoogle Scholar
  16. Burson JM, Aguilera G, Gross KW, Sigmund CD, 1994, Differential expression of angiotensin receptor 1A and 1B in mouse. Am J Physiol Endocrinol Metab. 267: E260–E267Google Scholar
  17. Carey RM, Siragy HM, 2003, Newly recognized components of the Renin-Angiotensin System: Potential Roles in cardiovascular and renal regulation. Endocrine Reviews. 24: 261–271PubMedCrossRefGoogle Scholar
  18. Carlsson PO, Berne C, Jansson L, 1998, Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia. 41: 127–133PubMedCrossRefGoogle Scholar
  19. Cassis LA, 1993, Role of angiotensin II in brown adipose thermogenesis during cold acclimation. Am J Physiol Endocrinol Metab. 265: E680–E685Google Scholar
  20. Cassis LA, English VL, Bharadwaj K, Boustany CM, 2004, Differential effects of local versus systemic angiotensin II in the regulation of leptin release from adipocytes. Endocrinology. 145: 169–174PubMedCrossRefGoogle Scholar
  21. Cassis LA, Marshall DE, Fettinger MJ, Rosenbluth B, Lodder RA, 1998, Mechanisms contributing to angiotensin II regulation of body weight. Am J Physiol Endocrinol Metab. 274: 867–876Google Scholar
  22. Chu KY, Lau T, Carlsson P, Leung PS, 2006, Angiotensin II type 1 receptor blockade improves β-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes. 55: 367–374PubMedCrossRefGoogle Scholar
  23. Crackower MA, Sarao R, Oudit GY, et al 2002, Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 417: 822–828PubMedCrossRefGoogle Scholar
  24. Crandall DL, Armellino DC, Busler DE, Mc Hendry-Rinde B, Kral JG, 1999, Angiotensin II receptor in human preadipocytes: role in cell cycle regulation. Endocrinology. 140: 154–158PubMedCrossRefGoogle Scholar
  25. Crandall DL, Herzlinger HE, Saunders BD, Armellino DC, Kral JG, 1994, Distribution of angiotensin receptors in rat and human adipocytes. J Lipid Res. 35: 1378–1385PubMedGoogle Scholar
  26. Dickson ME, Sigmund CD, 2006, Genetic basis of hypertension: revisiting Angiotensinogen. Hypertension. 48: 14–20PubMedCrossRefGoogle Scholar
  27. Duncan GE, Sierra ML, Zhou XH, 2004, Prevalence and trends of a Metabolic Syndrome phenotype among U.S. adolescents, 1999–2000. Diabetes Care. 27: 2438–2443PubMedCrossRefGoogle Scholar
  28. Engeli S, Negrel R, Sharma AM, 2000, Physiology of the adipose tissue renin-angiotensin system. Hypertension. 35: 1270–1277PubMedGoogle Scholar
  29. Fernández-Real JM, Ricart W, 2003, Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrine Reviews. 24: 278–301PubMedCrossRefGoogle Scholar
  30. Flegal KM, Carroll MD, Ogden CL, et al 2002, Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 288: 1723–1727PubMedCrossRefGoogle Scholar
  31. Ford ES, 2005, Prevalence of the Metabolic Syndrome defined by the International Diabetes Federation among adults in the US. Diabetes Care. 28: 2745–2749PubMedCrossRefGoogle Scholar
  32. Frederich RC, Kahn BB, Peach MJ, Flier JS, 1992, Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension. 19: 339–344PubMedGoogle Scholar
  33. Giacchetti G, Sechi LA, Rilli S, Carey RM, 2005, The renin angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 16 (3): 120–126PubMedCrossRefGoogle Scholar
  34. Goldstein BJ, Scalia R, 2004, Adiponectin: A novel Adipokyne linking adipocytes and vascular function. Journal of Clinical Endocrinology and Metabolism. 89: 2563–2568PubMedCrossRefGoogle Scholar
  35. Goodpaster BH, Krishnaswami S, Harris TB, et al 2005, Obesity, regional body fat distribution, and the Metabolic Syndrome in older men and women. Arch Intern Med. 165: 777–783PubMedCrossRefGoogle Scholar
  36. Goodpaster BH, Thaete FL, Kelley DE, 2000, Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. Am J Clin Nutr. 71: 885–892PubMedGoogle Scholar
  37. Govindarajan G, Eble DM, Lucchesi PA, Samarel AM, 2000, Focal adhesion kinase is involved in angiotensin II-mediated protein synthesis in cultured smooth vascular cells. Circ Res. 87: 710–716PubMedGoogle Scholar
  38. Griendling KK, Murphy TJ, Alexander RW, 1993, Molecular Biology of the rennin-angiotensin system. Circulation. 87: 1816–1828PubMedGoogle Scholar
  39. Hansson L, Lindholm LH, Niskanen L, et al 1999, Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomized trial. Lancet. 353: 611–6PubMedCrossRefGoogle Scholar
  40. Hardie DG, 2004, The AMP-activated protein kinase pathway - New players upstream and downstream. J Cell Sci. 117: 5479–5487PubMedCrossRefGoogle Scholar
  41. Heart Outcomes Prevention Evaluation Study Investigators, 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 342: 145–153Google Scholar
  42. Hirochi M, Hayashida W, Akishita M, et al 1999, Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative cross talk. Circ Res. 84: 876–882Google Scholar
  43. Hjorth SA, Schambye HT, Greenlee WJ, Schwartz TW, 1994, Identification of peptide binding residues in the extracellular domains of the AT1 receptor. J Biol Chem. 269: 30953–30959PubMedGoogle Scholar
  44. Horiuchi M, Hayashida W, Kambe T, Yamada T, Dzau VJ, 1997, Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activating protein kinase phosphatase-1 and induces apoptosis. J Biol Chem. 272: 19022–19026PubMedCrossRefGoogle Scholar
  45. Hotamisligil GS, Spiegelman BM, 1994, Tumor necrosis factor a: a key component of the obesity-diabetes link. Diabetes. 43: 1271–1278PubMedCrossRefGoogle Scholar
  46. Huang XC, Richards EM, Sumners C, 1996, Mitogen-activated protein kinases in rat brain neuronal cultures are activated by angiotensin II type 1 receptors and inhibited by angiotensin II type 2 receptors. J Biol Chem. 271: 15635–15641PubMedCrossRefGoogle Scholar
  47. James PT, Leach R, Kalamara E, Shayeghi M, 2001, The Worldwide obesity epidemic. Obes Res. 9: 228S–233SPubMedGoogle Scholar
  48. Jones BH, Stanridge MK, Moustaid N, 1997, Angiotensin II increased lipogenesis in 3T3-L1 and human adipose cells. Endocrinology. 138: 1512–1519PubMedCrossRefGoogle Scholar
  49. Julius S, Kjeldsen SE Webel, M, et al 2004, Outcomes in hypertensives patients at high risk of cardiovascular risk treated with regimens based on valsartan and amlodipine: the VALUE randomized trial. Lancet. 363: 2022–2231PubMedCrossRefGoogle Scholar
  50. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K, 2006 Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 116: 1784–1792PubMedCrossRefGoogle Scholar
  51. Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsson MS, 1998, Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to Angiotensin II. J Clin Endocrinol Metab. 83: 3925–3929PubMedCrossRefGoogle Scholar
  52. Ko SH, Hong OK, Kim JW, Ahn YB, Song KH, Cha BY, Son HY, Kim MJ, Jeong IK, Yoon KH, 2006, High glucose increases extracellular matrix production in pancreatic stellate cells by activating the renin-angiotensin system. J Cell Biochem. 98: 343–55PubMedCrossRefGoogle Scholar
  53. Konishi H, Kuroda S, Inada Y, Fujisawa Y, 1994, Novel subtype of human angiotensin II type 1 receptor: cDNA cloning and expression. Biochem Biophys Res Commun. 199: 467–474PubMedCrossRefGoogle Scholar
  54. Konoshita T, et al 2006, Tissue gene expression of renin-angiotensin system in human type 2 diabetic nephropathy. Diabetes Care. 29: 848–52PubMedCrossRefGoogle Scholar
  55. Kristiansen OP, Mandrup-Poulse T, 2005, Interleukin-6 and Diabetes: The good, the bad, or the indifferent? Diabetes. 54 (Suppl 2): S114–S124PubMedCrossRefGoogle Scholar
  56. Krssak M, Falk Petersen K, Dresner A, et al 1999, Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia. 42: 113–116PubMedCrossRefGoogle Scholar
  57. Lam KY, Leung PS, 2002, Regulation and expression of a rennin-angiotensin system in human pancreas and pancreatic endocrine tumors. Eur J Endocrinol, 146: 567–572PubMedCrossRefGoogle Scholar
  58. Lau T, Carlsson PO, Leung PS, 2004, Evidence for a local angiotensin system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia. 47: 240–248PubMedCrossRefGoogle Scholar
  59. Lastra G, Manrique C, Sowers, JR, 2006, Obesity and chronic kidney disease: The weight of the evidence. Adv Chronic Kidney Dis. 13: 365–373PubMedCrossRefGoogle Scholar
  60. Leung PS, Carlsson PO, 2001, Tissue renin-angiotensin system: its expression, localization, regulation and potential role in the pancreas. J Mol Endocrinol. 26: 155–164PubMedCrossRefGoogle Scholar
  61. Leung PS, Chappell MC, 2003, A local pancreatic renin-angiotensin system: endocrine and exocrine roles. Int J Biochem Cell Biol. 35: 838–846PubMedCrossRefGoogle Scholar
  62. Licata G, Scaglione R, Ganguzza A, et al 1994, Central obesity and hypertension. Relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subjects. Am J Hypertens. 7: 314–320PubMedGoogle Scholar
  63. Lorenzo O, Ruiz-Ortega M, Suzuki Y, et al 2002, Angiotensin III Activates Nuclear Transcription Factor-kB in Cultured Mesangial Cells Mainly via AT2 Receptors: Studies with AT1 Receptor-Knockout Mice. J. Am. Soc. Nephrol. 13: 1162PubMedCrossRefGoogle Scholar
  64. Lorenzo, C, Serrano-Rios M, Martinez-Larrad MT, et al 2006, Geographic variations of the International Diabetes Federation anf the National Cholesterol Education Program – Adult Treatment Panel III Definitions of the metabolic syndrome in nondiabetic subjects. Diabetes Care. 29: 685–691PubMedCrossRefGoogle Scholar
  65. Lupi et al 2006, The direct effects of the angiotensin converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. Eur J of Endocrinol. 154: 355–361CrossRefGoogle Scholar
  66. Madrid MI, Garcia-Duran M, Tornel J, De Gasparo M, Fenoy FJ, 1997, Effect of interactions between nitric oxide and angiotensin II on pressure natriuresis. Am J Physiol Regulatory Integrative Comp Physiol. 273: R1676–R1682Google Scholar
  67. Manrique C, Lastra G. Sowers JR, 2005, Hypertension and the Cardiometabolic Syndrome. Journal of Clinical Hypertension. 7: 471–476PubMedCrossRefGoogle Scholar
  68. Massiera F, Bloch-Faure M, Ceiler D, et al 2001, Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J. 15: 2727–2729PubMedGoogle Scholar
  69. Navar LG, 2004, The intrarenal renin-angiotensin system in hypertension. Kidney Intl. 65: 1522–1532CrossRefGoogle Scholar
  70. Nguyen G, Bouzhir L, Delarue F, Rondeau E, Giller T, Sraer JD, 2002, Pivotal role of the renin/Prorenin receptor in Angiotensin II production and cellular responses to Renin. J Clin Invest. 109: 1417–1427PubMedCrossRefGoogle Scholar
  71. Nickenig G, Harrison DG, 2002, The AT1-type angiotensin receptor in oxidative stress and atherogenesis. Part I: Oxidative stress and atherogenesis. Circulation. 105: 393–396PubMedCrossRefGoogle Scholar
  72. Nickenig G, Ostergren J, Struijke-Boudier H, 2006, Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers. JRAAS. 7: S1–S7PubMedGoogle Scholar
  73. Ouchi N, Ohishi M, Kihara S, et al 2003, Association of hypoadiponectinemia with impaired vasoreactivity. Journal of Hypertension. 42: 231–234CrossRefGoogle Scholar
  74. Ozono R, Wang ZQ, Moore AF, Inagami T, Siragy HM, Carey RM, 1997, Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension. 30: 1238–1246PubMedGoogle Scholar
  75. Pagano PJ, Chanock SJ, Siwik DA, Colucci WS, Clark JK, 1998, Angiotensin II induces p67phox mRNA expression and NADPH oxidase superoxide generation in rabbit aortic adventitial fibroblasts. Hypertension. 32: 331–337PubMedGoogle Scholar
  76. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB, 2003, The metabolic syndrome: Prevalence and risk factor findings in the US population from the third national health and nutrition examination survey, 1988 1994. Arch Int Med. 163: 427–436CrossRefGoogle Scholar
  77. Paula RD, Lima CV, Khosla MC, 1995, Angiotensin (1–7) potentiates hypotensive effect of bradykinin in conscious rats. Hypertension. 26: 1154–1159PubMedGoogle Scholar
  78. Peach MJ, 1977, Renin-angiotensin system: Biochemistry and mechanisms of action. Physiol Rev. 57: 313–370PubMedGoogle Scholar
  79. Pickup JC, 2004, Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 27: 813–823PubMedCrossRefGoogle Scholar
  80. Pittas AG, Joseph NA, Greenberg AS, 2004, Adipocytokines and insulin resistance. J Clin Endocrinol Metab. 89: 447–452PubMedCrossRefGoogle Scholar
  81. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal J, Michel J, 2000, Angiotensin II stimulates endothelial vascular cell adhesion molecule – 1 via nuclear factor κB activation induced by intracellular oxidative stress. Arterioscler thromb Vasc Biol. 20: 645–654PubMedGoogle Scholar
  82. Ran J, Hirano T, Adachi M, 2004, Angiotensin II type 1 receptor b locker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab. 287: E227–E232PubMedCrossRefGoogle Scholar
  83. Ravussin E, Smith SR, 2002, Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance and type 2 diabetes mellitus. Ann N.Y. Acad Sci. 967: 363–378PubMedCrossRefGoogle Scholar
  84. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M, 2005, Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation. 111: 2509–2517PubMedCrossRefGoogle Scholar
  85. Ruiz-Ortega M, Lorenzo O, Ruperez M, et al 2001, Systemic infusion of angiotensin II into normal rats activates nuclear factor κ-B and AP-1 in the kidney. Role of AT1 and AT2 receptors. Am J Pathol. 158: 1743–175PubMedGoogle Scholar
  86. Ruiz-Ortega M, Lorenzo O, Ruperez M, Kong S, Wittig B, Egido J, 2000, Angiotensin II activates nuclear transcription factor kB through AT1 and At2 in vascular smooth cells: molecular mechanisms. Circ Res. 86: 1266–1272PubMedGoogle Scholar
  87. Sadoshima J, 2000, Cytokine actions of angiotensin II. Circ Res. 86: 1187–1189PubMedGoogle Scholar
  88. Safonova I, Aubert J, Negrel R, Ailhaud G, 1997, Regulation by fatty acids of angiotensinogen gene expression in preadipose cells. Biochem J. 322 (Pt 1): 235–239PubMedGoogle Scholar
  89. Saward L, Zahradka P, 1997, Angiotensin II activates phosphatidylinositol 3-kinase in vascular smooth cells. Circ Res. 81: 249–25PubMedGoogle Scholar
  90. Schneider BS, Faust IM, Hemmes R, Hirsch J, 1981, Effects of altered adipose tissue morphology on plasma insulin levels in the rat. Am J Physiol. 240: E358–E362PubMedGoogle Scholar
  91. Senn JJ, Klover PJ, Nowak IA, et al 2003, Suppressor of Cytokine Signaling – 3 (SOCS-3), a potential mediator of Interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem. 278: 13740–13746PubMedCrossRefGoogle Scholar
  92. Sowers JR, 2002, Hypertension, angiotensin II and oxidative stress. N Engl J Med. 346: 1999–2001PubMedCrossRefGoogle Scholar
  93. Stein CJ, Colditz GA, 2004, The epidemic of obesity. J Clin Endocrinol Metab. 89: 2522–2525PubMedCrossRefGoogle Scholar
  94. Tahmasebi M, Puddefoot JR, Inwang ER, et al 1999, The tissue renin-angiotensin system in human pancreas. J Endocrinol. 161: 317–322PubMedCrossRefGoogle Scholar
  95. The DREAM Trial Investigators, 2006, Effect of ramipril on the incidence of diabetes. N Engl J Med. 355: 1551–62Google Scholar
  96. Tikellis C, Cooper ME, Thomas MC, 2006, Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes. Int J Biochem Cell Biol. 38: 737–51PubMedCrossRefGoogle Scholar
  97. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ, 2000, A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol. Chem. 275: 33238–33243PubMedCrossRefGoogle Scholar
  98. Tsutsumi Y, Matsubara H, Masaki H, et al 1999, Angiotensin II type 2 receptor overexpression activates the vascular kynin system and causes vasodilatation. J Clin Invest. 104: 925–935PubMedCrossRefGoogle Scholar
  99. Tuck ML, Sowers J, Dornfield L, Kledzik G, Maxwell M, 1981, The effect of weight reduction on blood pressure plasma renin activity and aldosterone levels in obese patients. N Eng J Med. 304: 930–933CrossRefGoogle Scholar
  100. Ushio-Fukai M, Alexander W, 2004, Reactive oxygen species as mediators of angiogenesis signaling: Role of NADPH oxidase. Mol Cell Biochem 264: 85–97PubMedCrossRefGoogle Scholar
  101. Ushio-Fukai M, Tabg Y, Fukai T, et al 2002, Novel role of gp91phox containing NADPH oxidase in vascular endothelial growth factor induced signaling and angiogenesis. Circ Res. 91: 1160–1167PubMedCrossRefGoogle Scholar
  102. Van HV, Ariapart P, Hoffstedt J, Lundkvist I, Bringman S, Arner P, 2000, Increased adipose angiotensinogen gene expression in human obesity. Obes Res. 8: 337–341Google Scholar
  103. Vidotti, DB, Casarinin DE, Cristovam PC, Leite CA, Boim MA, 2004, High glucose concentration stimulates renin activity and angiotensin II generation in mesangial cells. Am J Physiol Renal Physiol. 286: F1039–F1045PubMedCrossRefGoogle Scholar
  104. Wang HD, Hope SK, Du Y, Quinn MT, Cayatte AJ, Cohen RA, 1999, Paracrine role of adventitial superoxide anion in spontaneous tone in the isolated rat aorta in angiotensin II – induced hypertension. Hypertension. 33: 1225–1232PubMedGoogle Scholar
  105. Watanabe, T, Thomas A, Barker CB, 2005, Angiotensin II and the endothelium: Diverse signals and effects. Hypertension. 45: 163–169PubMedCrossRefGoogle Scholar
  106. Yusuf S, Ostergren JB Gerstein HC, et al 2005, Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation. 112: 48–53PubMedCrossRefGoogle Scholar
  107. Zuo L Ushio-Fukai M, Hilenski LL, Alexander RW, 2004, Microtubules regulate angiotensin II type 1 receptor and Rac1 localization in caveolae/lipid rafts: role in redox signaling. Arterioscler Thromb Vasc Biol. 24: 1223–1228PubMedCrossRefGoogle Scholar
  108. Zuo L, Ushio-Fukai M, Ikeda S, Hilenski L, Patrushev N, Alexander RW, 2005, Caveolin 1 is Essential for Activation of Rac-1 and NADPH oxidase After Angiotensin II Type 1 receptor stimulation in Vascular Smooth Muscle Cells: Role in Redox Signaling and Vascular Hyperthophy. Arterioscler Thromb Vasc Biol. 25: 1824–1830PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2007

Authors and Affiliations

  • Guido Lastra
    • 1
  • Camila Manrique
    • 1
  • James R. Sowers
    • 1
  1. 1.Department of Internal MedicineUniversity of Missouri-ColumbiaColumbiaUSA

Personalised recommendations